The increasing incidence of cancer among young individuals underscores the importance of preserving reproductive function and improving experimental models for the study of chemotherapy-induced testicular failure. The aim of this study was to conduct a comparative evaluation of cytostatic agents from different pharmacological classes in a mouse model of testicular dysfunction. Male Balb/c mice were treated with cyclophosphamide (250 mg/kg), doxorubicin (10 mg/kg), or cisplatin (10 mg/kg). Body weight, hemato- logical parameters, survival, social activity, anxiety levels, and sperm parameters were assessed at 1, 4, and 8 weeks post-treatment. Doxorubicin caused early and pronounced toxicity, including weight loss, hematopoietic suppression, reduced sperm count, motility, and viability, along with an increased proportion of abnormal forms as early as one week after administration. By week 4, complete aspermatogenesis was observed, accompanied by persistent behavioral impairments and increased lethality, without recovery by the end of the study. In the cyclophosphamide group, body weight and hematological parameters stabilized within 4 weeks, although irreversible anxiety elevation and transient reduction in social activity were noted. Oligospermia peaked at week 4, accompanied by decreased motility and viability, while sperm count and morphology remained impaired up to week 8. Cisplatin demonstrated the mildest and predominantly revers- ible effects. Body weight progressively increased, hematological alterations were moderate with subsequent recovery, and social activity was generally preserved except for a transient decline at week 4. Anxiety levels showed a decreasing trend, while moderate oligospermia was detected without significant morphological abnormalities. By week 8, sperm count and motility showed marked improvement. In summary, cyclophos- phamide represents the most suitable agent for modeling testicular failure with partial functional recovery, doxorubicin induces irreversible gonadotoxicity, and cisplatin may be employed to study mild, reversible forms of gonadal impairment.